Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01296620 · ClinicalTrials.gov registry record · Phase 3
Ulimorelin Study of Efficacy and Safety (ULISES 008)
A Phase 3 study, sponsored by Tranzyme.
- Completed
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
NCT01296620 is a Phase 3 study that has completed, run by Tranzyme. The registered enrollment target is 330 participants.
The verdict
NCT01296620, a Phase 3 study, has completed, sponsored by Tranzyme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
Study Summary
Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection
Interventions
- DRUG Ulimorelin Intravenously (IV)
- DRUG 5% dextrose in water
- DRUG Ulimorelin Invtravenously (IV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01296620
The ClinicalTrials.gov registry entry for NCT01296620 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tranzyme, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ulimorelin Intravenously (IV) is the first listed.
NCT01296620 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01296620 about?
NCT01296620 is a clinical study titled "Ulimorelin Study of Efficacy and Safety (ULISES 008)". Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection
What is the current status of trial NCT01296620?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2011-02. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01296620?
The interventions under investigation include: Ulimorelin Intravenously (IV) (DRUG), 5% dextrose in water (DRUG), Ulimorelin Invtravenously (IV) (DRUG).
Who is sponsoring clinical trial NCT01296620?
This trial is sponsored by Tranzyme, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.